The global microbiome therapeutics market size is expected to reach USD 973.63 million by 2030, garnering a CAGR of 31.24% from 2022 to 2030, according to this report. The rise in prevalence of target diseases such as gastrointestinal diseases, diabetes, and immunological indications is anticipated to drive growth. The adoption of fecal microbial transplant and the availability of FMT in form of capsules has enhanced the acceptance of microbiome therapeutics amongst patients with C. difficile infection. Furthermore, increasing R&D investments and government support are anticipated to further drive the market.
FMT has demonstrated a considerable success rate in the treatment of patients with recurrent C. difficile infection. Thus, the growing prevalence of the condition is expected to escalate the demand for microbiome therapies. For instance, as per Therapeutic Advancements in Gastroenterology Journal, in 2022, after initial occurrence, 25-65% of the patients in the U.S. experience recurrent CDI which makes the treatment complex.
There has been increasing demand to understand the human microbiome to be able to transform the potential of the microbiome for use in therapeutics. This has led to an increase in R&D which has been driving the presence of a stronger pipeline in the market. Candidates such as CH-0601, and M-008 are under development for diabetes treatment. Moreover, companies are receiving heightened funding from investors owing to enhanced interest in the field. For instance, in July 2021, Vedanta Biosciences received funding of USD 68 million for phase III development of its product VE303 for high-risk CDI treatment.
Key players operating in the global market are engaged in extensive research to gain an advantage over other players. The companies are engaged in taking efforts to develop and manufacture products to be used for therapies. Numerous products are in the initial stages of trials and are expected to be developed and used in the market. For instance, in 2021, Ferring Pharmaceuticals and Rebiotix announced Phase III data of their candidate RBX2660 for the reduction in recurring C. difficile infection. The candidate further has a fast track, orphan, and breakthrough therapy designations from the FDA.
This product will be delivered within 1-3 business days.
FMT has demonstrated a considerable success rate in the treatment of patients with recurrent C. difficile infection. Thus, the growing prevalence of the condition is expected to escalate the demand for microbiome therapies. For instance, as per Therapeutic Advancements in Gastroenterology Journal, in 2022, after initial occurrence, 25-65% of the patients in the U.S. experience recurrent CDI which makes the treatment complex.
There has been increasing demand to understand the human microbiome to be able to transform the potential of the microbiome for use in therapeutics. This has led to an increase in R&D which has been driving the presence of a stronger pipeline in the market. Candidates such as CH-0601, and M-008 are under development for diabetes treatment. Moreover, companies are receiving heightened funding from investors owing to enhanced interest in the field. For instance, in July 2021, Vedanta Biosciences received funding of USD 68 million for phase III development of its product VE303 for high-risk CDI treatment.
Key players operating in the global market are engaged in extensive research to gain an advantage over other players. The companies are engaged in taking efforts to develop and manufacture products to be used for therapies. Numerous products are in the initial stages of trials and are expected to be developed and used in the market. For instance, in 2021, Ferring Pharmaceuticals and Rebiotix announced Phase III data of their candidate RBX2660 for the reduction in recurring C. difficile infection. The candidate further has a fast track, orphan, and breakthrough therapy designations from the FDA.
Microbiome Therapeutics Market Report Highlights
- By type, the FMT segment held the largest market share in 2021 owing to its use as a therapeutic option in the treatment of recurrent C. difficile infection
- By application, the C. difficile segment held the largest share due to the use of microbiome therapeutics in the treatment of recurrent infections
- North America dominated the global market in 2021 and is anticipated to be the fastest growing region owing to the high adoption rate of novel therapeutics and the presence of regulatory support
- Partnerships between big pharma companies and smaller companies that are developing microbiome therapeutics are highly common which allows these companies to receive funding and use the expertise of big pharma these companies
- Key market players include OpenBiome, Seres Therapeutics Inc., 4D Pharma Plc., Locus Biosciences, Inc., Enterome SA, Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome, Rebiotix Inc., and Vedanta Bioscience, Inc.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Microbiome Therapeutics Market: Methodology And Scope1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.2 Volume price analysis (model 2)
1.6.2.1 Approach 2: Volume price analysis
1.6.2.2 Revenue modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 Microbiome Therapeutics Market: Executive Summary
2.1 Market summary
Chapter 3 Microbiome Therapeutics Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing number of strategic collaborations
3.3.1.2 Rise in prevalence of target diseases
3.3.1.3 Advancements in microbiome technology to develop novel products
3.3.1.4 Increasing R&D in order to understand the human microbiome
3.3.2 Market Restraint Analysis
3.3.2.1 Stringent regulatory guidelines
3.3.2.2 High cost of development, and production
3.4 Porter’s Five Forces Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Regulatory Framework
3.7 User Perspective Analysis
Chapter 4 Microbiome Therapeutics Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Major deals & strategic alliances analysis
4.2.1 Joint Ventures
4.2.2 Licensing and Partnerships
4.2.3 Technological Collaborations
4.3 Company/Competition Categorization
4.4 Vendor Landscape
4.4.1 List Of Key Distributors and Channel Partners
4.4.2 Key Customers
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
Chapter 6 Microbiome Therapeutics Market: Type Business Analysis
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2021 & 2030
5.3 Global Microbiome Therapeutics Market, By Type, 2018 To 2030
5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1 FMT
5.4.1.1 FMT Market 2018 - 2030 (USD Million)
5.4.2 Microbiome Drugs
5.4.2.1 Microbiome Drugs Market, 2018 - 2030 (USD Million)
Chapter 6 Microbiome Therapeutics Market: Application Business Analysis
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2021 & 2030
6.3 Global Microbiome Therapeutics Market, By Application, 2018 To 2030
6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1 C. difficile
6.4.1.1 C. difficile Market 2018 - 2030 (USD Million)
6.4.2 Cohn's Disease
6.4.2.1 Cohn's Disease Market, 2018 - 2030 (USD Million)
6.4.3 Inflammatory Bowel Disease
6.4.3.1 Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
6.4.4 Diabetes
6.4.4.1 Diabetes Market, 2018 - 2030 (USD Million)
6.4.5 Others
6.4.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 7 Microbiome Therapeutics Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2021 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
7.7 North America
7.7.1 North America Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.7.3 Canada
7.7.3.1 Canada Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8 Europe
7.8.1 Europe Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 Germany
7.8.3.1 Germany Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.4 France
7.8.4.1 France Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.5 Italy
7.8.5.1 Italy Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.6 Spain
7.8.6.1 Spain Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9 Asia Pacific
7.9.1 Asia-Pacific Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9.3 China
7.9.3.1 China Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.9.4 India
7.9.4.1 India Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.4 Australia
7.8.4.1 Australia Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.5 South Korea
7.8.5.1 South Korea Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.10 Latin America
7.10.1 Latin America Microbiome Therapeutics Market Market, 2018 - 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.10.3 Mexico
7.10.3.1 Mexico Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 Argentina
7.8.3.1 Argentina Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11 MEA
7.11.1 MEA Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11.2 Saudi Arabia
7.11.2.1 Saudi Arabia Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
7.11.3 UAE
7.11.3.1 Uae Microbiome Therapeutics Market, 2018 - 2030 (USD Million)
Chapter 8 Microbiome Therapeutics Market: Company Profiling
8.1 Company Profiles
8.1.1. OpenBiome
8.1.1.1 Company overview
8.1.1.2 Financial Performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2. Seres Therapeutics Inc.
8.1.2.1 Company overview
8.1.2.2 Financial Performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3. 4D Pharma plc.
8.1.3.1 Company overview
8.1.3.2 Financial Performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4. Locus Biosciences, Inc.
8.1.4.1 Company overview
8.1.4.2 Financial Performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5. Enterome SA
8.1.5.1 Company overview
8.1.5.2 Financial Performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6. Finch Therapeutics Group, Inc.
8.1.6.1 Company overview
8.1.6.2 Financial Performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7. Intralytix, Inc.
8.1.7.1 Company overview
8.1.7.2 Financial Performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8. Microbiotica
8.1.8.1 Company overview
8.1.8.2 Financial Performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9. Second Genome
8.1.9.1 Company overview
8.1.9.2 Financial Performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10. Rebiotix Inc.
8.1.10.1 Company overview
8.1.10.2 Financial Performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11. Vedanta Bioscience, Inc.
8.1.11.1 Company overview
8.1.11.2 Financial Performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Microbiome Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 6 Global Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 7 North America Microbiome Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 9 North America Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 10 U.S. Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 12 Canada Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 14 Europe Microbiome Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 15 Europe Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 16 Europe Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 17 U.K. Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 18 U.K. Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 19 Germany Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 20 Germany Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 21 France Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 22 France Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 23 Italy Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 24 Italy Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 25 Spain Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 26 Spain Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 27 Asia Pacific Microbiome Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 30 China Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 31 China Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 32 Japan Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 33 Japan Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 34 India Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 35 India Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 36 Australia Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 37 Australia Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 38 South Korea Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 39 South Korea Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 40 Latin America Microbiome Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 41 Latin America Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 42 Latin America Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 43 Brazil Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 44 Brazil Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 45 Mexico Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 46 Mexico Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 47 Argentina Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 48 Argentina Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 49 MEA Microbiome Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 50 MEA Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 51 MEA Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 52 South Africa Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 53 South Africa Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 54 Saudi Arabia Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 56 UAE Microbiome Therapeutics Market, By Type, 2018 - 2030 (USD Million)
Table 57 UAE Microbiome Therapeutics Market, By Application, 2018 - 2030 (USD Million)
List of Figures
FIG. 1 Microbiome Therapeutics Market Segmentation
FIG. 2 Market Research Process
FIG. 3 Information Procurement
FIG. 4 Primary Research Pattern
FIG. 5 Market Research Approaches
FIG. 6 Value-Chain-Based Sizing & Forecasting
FIG. 7 QFD Modeling For Market Share Assessment
FIG. 8 Market Formulation & Validation
FIG. 9 Microbiome Therapeutics Market, Segment Outlook
FIG. 10 Microbiome Therapeutics Market, Competitive Outlook
FIG. 11 Microbiome Therapeutics Market Outlook (2021)
FIG. 12 Penetration & Growth Prospect Mapping
FIG. 13 User Perspective Analysis
FIG. 14 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 15 Global Percentage Of Population, By Age Group, 2050 And 2000
FIG. 16 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 17 Porter’s Five Forces Analysis
FIG. 18 PESTLE Analysis
FIG. 19 Ansoff Matrix
FIG. 20 Heat Map Analysis
FIG. 21 Company Market Position Analysis
FIG. 22 Company Market Position Analysis
FIG. 23 Market Differentiators
FIG. 24 Strategy Mapping
FIG. 25 Microbiome Therapeutics Market: Type Movement Analysis
FIG. 26 Segment Dashboard
FIG. 27 Microbiome Therapeutics Market Type Outlook: Key Takeaways
FIG. 28 FMT Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 29 Microbiome Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 30 Microbiome Therapeutics Market: Application Movement Analysis
FIG. 31 Segment Dashboard
FIG. 32 Microbiome Therapeutics Market Application Outlook: Key Takeaways
FIG. 33 C.Difficile Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 34 Crohn's Disease Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 35 Inflammatory Bowel Disease Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 36 Diabetes Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 37 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 38 Regional Outlook, 2021 & 2030
FIG. 39 Regional Market Dashboard
FIG. 40 Regional Market Place: Key Takeaways
FIG. 41 North America, SWOT Analysis
FIG. 42 Europe, SWOT Analysis
FIG. 43 Asia Pacific, SWOT Analysis
FIG. 44 Latin America, SWOT Analysis
FIG. 45 MEA, SWOT Analysis
FIG. 45 North America
FIG. 46 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 47 U.S.
FIG. 48 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 49 Canada
FIG. 50 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 51 Europe
FIG. 52 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 53 U.K.
FIG. 54 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 55 Germany
FIG. 56 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 57 France
FIG. 58 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 59 Italy
FIG. 60 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 61 Spain
FIG. 62 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 63 Asia Pacific
FIG. 64 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 65 Japan
FIG. 66 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 67 China
FIG. 68 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 69 India
FIG. 70 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 71 Australia
FIG. 72 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 73 South Korea
FIG. 74 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 75 Latin America
FIG. 76 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 77 Brazil
FIG. 78 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 79 Mexico
FIG. 80 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 81 Argentina
FIG. 82 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 83 MEA
FIG. 84 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 85 South Africa
FIG. 86 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 87 Saudi Arabia
FIG. 88 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 89 UAE
FIG. 90 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
FIG. 91 Strategy Mapping
Companies Mentioned
- OpenBiome
- Seres Therapeutics Inc.
- 4D Pharma plc.
- Locus Biosciences, Inc.
- Enterome SA
- Finch Therapeutics Group, Inc.
- Intralytix, Inc.
- Microbiotica
- Second Genome
- Rebiotix Inc.
- Vedanta Bioscience, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | August 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 89.55 Million |
| Forecasted Market Value ( USD | $ 973.63 Million |
| Compound Annual Growth Rate | 31.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
